EXACT Therapeutics reports H1 2025 results amid clinical trial progress

EXACT Therapeutics announced its interim results for the first half of 2025, detailing progress in its clinical programs. A major milestone was achieved in June 2025 with the first patient dosed in the Phase 2 ENACT clinical trial for locally advanced pancreatic cancer, following a NOK 145 million private placement in December 2024. The ACTIVATE Phase 1 trial also yielded strong final results, demonstrating tumor shrinkage in 6 of 9 patients receiving Acoustic Cluster Therapy (ACT) with chemotherapy.

The company further strengthened its intellectual property with a core patent granted in the United States, a pancreatic cancer treatment patent in Japan, and a CNS treatment patent in the UK, extending coverage to at least 2040. Preclinical data in glioblastoma showed encouraging results, with a greater than twofold increase (+127%–145%) in radiopharmaceutical uptake in brain tumors. Total operating expenses for the first half of 2025 reached NOK 45.8 million, with a net result of NOK -49.2 million.

As of June 30, 2025, total assets were NOK 101.3 million, and the cash balance stood at NOK 58.5 million. The company's primary focus remains advancing the ENACT trial, with an initial safety read-out expected in the second half of 2025. This safety read-out will also trigger the exercise of warrants from the December 2024 capital raise.